Advanced Search

 

Study ID Status Title Patient Level Data
DIX110434 Completed A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) Study Listed on ClinicalStudyDataRequest.com
DIX110825 Completed A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects
DPB100925 Completed A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension Study Listed on ClinicalStudyDataRequest.com
DPB106652 Terminated GW823093 Japan Phase IIa Mono
DPB106653 Completed PK/PD study of GW823093 in Japanese subjects with T2DM A single-blind, placebo controlled, randomized, multi-dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GW823093C administered orally for 7 days in Japanese subjects with type 2 diabetes
DPB107246 Withdrawn A multi-center, double-blind, parallel-group, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of denagliptin in subjects with type 2 diabetes mellitus
E3870651 Completed A randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol are Achieved in Two Marketed Formulations
E7411153 Completed An exploratory study to investigate the inflammatory response during a cold sore episode
EBD100729 Terminated A double-blind, placebo-controlled phase I/II study in patients with mild to moderate ulcerative colitis treated with GI-270384X, an oral ICAM-1 and E-selectin inhibitor
EGF 20002 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
EGF10015 Completed A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients
EGF100161 Active, Not Recruiting An open-label, multicenter, Phase I/II dose escalation study of oral GW572016 in combination with docetaxel (Taxotere) plus trastuzumab (Herceptin) in subjects previously untreated for ErbB2-overexpressing metastatic breast cancer
EGF10021 Completed A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination with docetaxel (TAXOTERE)
EGF10027 Completed A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients with Treatment- Naive Breast Cancer
EGF100642 Completed Phase II Clinical Study of GW572016 in Patients with Advanced or Metastatic Breast Cancer
EGF101950 Withdrawn Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib
EGF102580 Completed A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination with Paclitaxel as Neoadjuvant Therapy in Patients with Newly Diagnosed Inflammatory Breast Cancer
EGF102980 Completed A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients with Relapsed Adenocarcinoma of the Esophagus, including Tumors of the Gastroesophageal Junction and Gastric Cardia
EGF102988 Completed A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
EGF103009 Completed A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients with Relapsed or Refractory Inflammatory Breast Cancer
EGF103659 Active, Not Recruiting An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
EGF103890 Active, Not Recruiting A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
EGF103892 Active, Not Recruiting A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination with Carboplatin, Paclitaxel, and Herceptin in Patients with Metastatic Breast Cancer
EGF104334 Completed A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
EGF104383 Active, Not Recruiting A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.